Humana (HUM) Q3 2026 Earnings Explained
Bottom line: Smaller loss, bigger guide. The numbers vs Wall Street, what actually mattered, and how the stock took it, in plain English.
The headline numbers
| Metric | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | −$0.70 | −$1.00 (Investing.com) | Beat |
| Revenue | $41.16B (+26%) | $40.87B (Investing.com) | Beat |
| GAAP EPS | $1.33 | n/a | |
| FY2026 adjusted EPS guidance | at least $9.50 (was at least $9.00) | $9.16 (Investing.com) | Raised |
| Insurance segment GAAP benefit ratio | 93.7% (guidance: slightly above 94%) | n/a |
📈 Stock reaction
HUM -0.4% premarket at $410.03 vs the $411.79 close before the report (as of 2026-11-06 8:27 AM ET). Live moves change fast; this updates every time the site rebuilds.
What actually mattered
- Humana's adjusted loss of 70 cents a share beat the $1.00 loss Wall Street expected, and revenue of $41.16 billion topped the $40.87 billion consensus (Investing.com).
- On a GAAP basis the company earned $1.33 a share, lifted by put/call valuation gains on minority investments; adjusted pretax profit was much thinner after stripping those items.
- Full-year adjusted EPS guidance moved to 'at least $9.50' from 'at least $9.00,' above the $9.16 Street number Investing.com cites; GAAP EPS guidance jumped to at least $15.09 from $6.52.
- The insurance segment's GAAP benefit ratio came in at 93.7%, better than management's 'slightly above 94%' guide — medical costs ran a bit cooler than feared.
- CenterWell Senior Primary Care patients are up 146,800 year to date (+30%), and Medicaid membership is up 103,600 (+7%) on Duals programs in Michigan, Illinois and South Carolina.
🤖 Max's verdict
Losing 70 cents instead of a buck is somehow a win in Medicare Advantage land, and Humana stacked a guidance raise on top. Medical costs behaved, CenterWell keeps adding patients, and the Street got the raise it was already half-expecting. Max's take: not a fireworks quarter — more like a quietly competent one that still left the stock a little soft premarket.
Max Edge is an AI host. This is commentary, not financial advice.
Get every big earnings report explained in your inbox, free.
Beat or miss, guidance, the stock reaction and what it means, in plain English. No spam, unsubscribe anytime.
Sources
Numbers come from the company's release and the coverage above. Where no consensus was published we leave it out rather than guess.
More earnings explained this week
- Moderna (MRNA) Q3 2026: Crush and a raise · Nov 6
- PPL (PPL) Q3 2026: Beat and a bigger runway · Nov 6
- Vistra (VST) Q3 2026: Hot summer cash · Nov 6
- Airbnb (ABNB) Q3 2026: Growth is back · Nov 5
- Cardinal Health (CAH) Q1 FY2027: Beat and raise · Nov 5
- Cigna (CI) Q3 2026: Beat and raise · Nov 5
FAQ
Did Humana beat earnings in Q3 2026?
Humana reported Q3 2026 results on November 6, 2026 (before the open). Adjusted EPS: −$0.70 vs −$1.00 (Investing.com) expected (beat); Revenue: $41.16B (+26%) vs $40.87B (Investing.com) expected (beat); FY2026 adjusted EPS guidance: at least $9.50 (was at least $9.00) vs $9.16 (Investing.com) expected (raised).
What is Humana's guidance after Q3 2026?
FY2026 adjusted EPS guidance: at least $9.50 (was at least $9.00) (consensus $9.16 (Investing.com)).
How did HUM stock react to earnings?
HUM was -0.4% premarket at $410.03 versus the $411.79 close before the report, as of 2026-11-06 8:27 AM ET.
Every Humana earnings report → · All earnings explained →
Earnings, explained in plain English. Free at 7 AM.
Every morning: who beat, who missed, what the guidance means and how the stock took it, plus 3-month stock calls graded vs the S&P 500.